Belharra Therapeutics
Belharra Therapeutics is a privately held, next-generation chemoproteomics company headquartered at 3985 Sorrento Valley Boulevard, Suite C, San Diego, California, that is building small molecule therapeutics against targets the industry has long considered undruggable. Its Searchlight platform is an unbiased chemoproteomics screening system designed to illuminate novel, previously invisible binding pockets on high-value proteins across the proteome — the company states it can identify small molecule binders for any binding site, on any protein, in any conformational state, in any cell type, and reported having identified more than four thousand drug-like pocket probes by January 2024. The company was incubated and supported by Versant Ventures out of foundational chemoproteomics research at The Scripps Research Institute, with co-founders including Christopher G. Parker and Benjamin Cravatt of Scripps Research and Stuart Schreiber of the Broad Institute of MIT and Harvard. Jeff Jonker was hired as chief executive officer in September 2021, and the company debuted publicly in January 2023 with $130 million in hand — a $50 million Series A led by Versant Ventures plus an $80 million upfront payment from a multi-year Genentech collaboration spanning oncology, immuno-oncology, autoimmune and neurodegenerative disease. In June 2024 it announced a strategic immunology collaboration with Sanofi carrying up to $40 million in upfront and near-term milestone payments, and in January 2025 it appointed Sean Buchanan as chief scientific officer. Belharra runs no developer program and publishes no product API, developer portal, API reference, or SDK. The only machine-readable surface reachable without credentials is the WordPress REST content API behind belharratx.com, catalogued here.
Belharra Therapeutics publishes 8 APIs on the APIs.io network, including Custom Types API, Discovery API, Media API, and 5 more. Tagged areas include Company, biotechnology, pharmaceuticals, chemoproteomics, and drug-discovery.
Belharra Therapeutics’ developer surface includes product news, authentication, and 27 more developer resources.
Kin Score
Kin Score
How this is scored →scored 2026-08-12 · rubric v0.11.0
APIs 8
Individual APIs this provider publishes, each with its own machine-readable definition.
Belharra Therapeutics Custom Types API
Belharra's three custom post types — press-release (4 items), company-news (21 items) and multimedia-file (10 items).
Belharra Therapeutics Discovery API
Route, type, taxonomy, status and author discovery documents.
Belharra Therapeutics Media API
Media library (430 attachments at harvest time).
Belharra Therapeutics Oembed API
oEmbed 1.0 provider endpoint for belharratx.com URLs.
Belharra Therapeutics Pages API
Corporate pages (29 published at harvest time).
Belharra Therapeutics Posts API
Blog/news archive (10 published at harvest time), categorised as Company News or Press Releases.
Belharra Therapeutics Search API
Cross-content search across published objects (74 searchable records at harvest time).
Belharra Therapeutics Taxonomy API
Categories and tags. Two categories are registered (Company News, Press Releases); the post_tag taxonomy is registered but empty.
Scroll for all 8
Security Posture 2
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 3
MCP servers, agent skills, and machine-readable catalogs
Design & Contract 5
Pagination, idempotency, versioning, errors, and events
Build 1
SDKs, sample code, and the tooling you integrate with
Access & Security 2
Authentication, authorization, and security posture
Operate 2
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 7
The organization behind the API
Scroll for all 7
Other 7
Properties that don't map to a standard resource type
Scroll for all 7